Stay informed with our
free newsletters

Hikma launches Rufinamide Tablets

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it launched Rufinamide Tablets, the generic equivalent of Banzel

Rufinamide is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in paediatric patients 1 year of age and older and in adults.

According to IQVIA, US sales of Rufinamide Tablets, 200mg and 400mg, were approximately $285 million in the 12 months ending April 2021.

“We are proud to be among the first wave of generics to provide this important medicine,” said Brian Hoffmann, President of Hikma Generics. “Hikma also markets Rufinamide Oral Suspension and we are pleased to add this new formulation to our portfolio. This launch demonstrates our ability to successfully deliver on our pipeline and launch new products, improving patients’ access to high-quality generic medicines.”

Global Constrained Peptide Drugs Market - Analysis and Forecast, 2023-2031

Global Constrained Peptide Drugs Market - Analysis and Forecast, 2023-2031

Focus on Peptide Type, Product, and Country Analysis

Download free sample pages

Source: Hikma
Date: Jun 24, 2021


Share this news: